BID | 224.76 | ASK | 225.00 | ||
Open | 221.50 | Previous Close | 214.80 | ||
Pre-Market | 218.82 | After-Market | - | ||
4.02 1.87% | - - |
Target Price | 328.70 | Analyst Rating | Hold 2.56 | |
Potential % | 46.38 | Finscreener Ranking | ★★★+ 51.04 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★★ 50.59 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★★★ 66.87 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 14.59 | Earnings Rating | Strong Sell | |
Market Cap | 35.33B | Earnings Date | 11th Aug 2022 | |
Alpha | -0.00 | Standard Deviation | 0.10 | |
Beta | 1.10 |
Today's Price Range 220.36226.63 | 52W Range 173.45526.00 | 5 Year PE Ratio Range 29.20124.90 |
Summary:
Neutral
Technical Indicators: | Neutral |
Moving Averages: | Sell |
Performance | |||
---|---|---|---|
1 Week | -3.72% | ||
1 Month | 9.01% | ||
3 Months | -2.22% | ||
6 Months | -40.01% | ||
1 Year | -57.58% | ||
3 Years | -26.94% | ||
5 Years | 10.35% | ||
10 Years | 392.66% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | 10.89 | |||
ROE last 12 Months | 9.02 | |||
ROA (5Y Avg) | 3.95 | |||
ROA last 12 Months | 5.96 | |||
ROC (5Y Avg) | 12.71 | |||
ROC last 12 Months | 6.96 | |||
Return on invested Capital Q | 0.67 | |||
Return on invested Capital Y | 0.91 | |||
Assets Turnover | 0.30 | |||
Receivables Turnover | 6.70 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
41.40 | ||||
2.73 | ||||
8.34 | ||||
67.00 | ||||
-12.60 | ||||
2.82 | ||||
51.88 | ||||
69.35 | ||||
30.92B | ||||
Forward PE | 41.90 | |||
PEG | 1.33 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.40 | ||||
1.80 | ||||
0.16 | ||||
0.24 | ||||
18.80 | ||||
Leverage Ratio | 1.40 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
68.80 | ||||
19.40 | ||||
25.70 | ||||
27.00 | ||||
14.53 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
3.53B | ||||
22.47 | ||||
8.95 | ||||
10.93 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q01 2022 | 0.87 | 1.07 | 22.99 |
Q04 2021 | 0.50 | 0.75 | 50.00 |
Q03 2021 | 1.24 | 1.45 | 16.94 |
Q02 2021 | 1.36 | 1.87 | 37.50 |
Q01 2021 | 1.36 | 1.89 | 38.97 |
Q04 2020 | 1.21 | 1.22 | 0.83 |
Q03 2020 | 0.77 | 1.02 | 32.47 |
Q02 2020 | 0.72 | 0.62 | -13.89 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
6/2022 QR | 0.63 | -35.71 | Negative |
9/2022 QR | 1.10 | -1.79 | Negative |
12/2022 FY | 4.09 | -1.21 | Negative |
12/2023 FY | 5.34 | 1.14 | Positive |
Next Report Date | 11th Aug 2022 |
Estimated EPS Next Report | 0.63 |
Estimates Count | 7 |
EPS Growth Next 5 Years % | 31.20 |
Volume Overview | |
---|---|
Volume | 527.38K |
Shares Outstanding | 157.10K |
Shares Float | 136.43M |
Trades Count | 15.48K |
Dollar Volume | 118.19M |
Avg. Volume | 1.09M |
Avg. Weekly Volume | 884.11K |
Avg. Monthly Volume | 1.06M |
Avg. Quarterly Volume | 1.34M |
Illumina Inc. (NASDAQ: ILMN) stock closed at 214.8 per share at the end of the most recent trading day (a -3.67% change compared to the prior day closing price) with a volume of 802.91K shares and market capitalization of 35.33B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 7850 people. Illumina Inc. CEO is Francis A. DeSouza.
The one-year performance of Illumina Inc. stock is -57.58%, while year-to-date (YTD) performance is -43.54%. ILMN stock has a five-year performance of 10.35%. Its 52-week range is between 173.45 and 526, which gives ILMN stock a 52-week price range ratio of 14.59%
Illumina Inc. currently has a PE ratio of 41.40, a price-to-book (PB) ratio of 2.73, a price-to-sale (PS) ratio of 8.34, a price to cashflow ratio of 67.00, a PEG ratio of 2.32, a ROA of 5.96%, a ROC of 6.96% and a ROE of 9.02%. The company’s profit margin is 14.53%, its EBITDA margin is 25.70%, and its revenue ttm is $3.53 Billion , which makes it $22.47 revenue per share.
Of the last four earnings reports from Illumina Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.63 for the next earnings report. Illumina Inc.’s next earnings report date is 11th Aug 2022.
The consensus rating of Wall Street analysts for Illumina Inc. is Hold (2.56), with a target price of $328.7, which is +46.38% compared to the current price. The earnings rating for Illumina Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Illumina Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Illumina Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 18.60, ATR14 : 9.61, CCI20 : 60.68, Chaikin Money Flow : 0.24, MACD : 5.36, Money Flow Index : 64.25, ROC : 6.50, RSI : 45.23, STOCH (14,3) : 54.24, STOCH RSI : 0.00, UO : 51.23, Williams %R : -45.76), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Illumina Inc. in the last 12-months were: Aimee L. Hoyt (Option Excercise at a value of $0), Aimee L. Hoyt (Sold 2 274 shares of value $798 250 ), Alexander Aravanis (Sold 12 404 shares of value $5 013 237 ), Charles E. Dadswell (Option Excercise at a value of $0), Charles E. Dadswell (Sold 3 202 shares of value $1 325 415 ), Francis A. DeSouza (Option Excercise at a value of $0), Joydeep Goswami (Option Excercise at a value of $0), Kevin Carl Pegels (Option Excercise at a value of $0), Phillip G. Febbo (Option Excercise at a value of $0), Phillip G. Febbo (Sold 2 988 shares of value $1 122 530 ), Sam A. Samad (Option Excercise at a value of $0), Susan H. Tousi (Option Excercise at a value of $0), Susan H. Tousi (Sold 2 250 shares of value $914 497 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Moderate Buy | Moderate Buy | Moderate Buy |
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (76% of 2020 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 16% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.
CEO: Francis A. DeSouza
Telephone: +1 858 202-4500
Address: 200 Illumina Way, San Diego 92122, CA, US
Number of employees: 7 850
Fri, 22 Jul 2022 03:45 GMT Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Illumina (ILMN) and Ionis Pharmaceuticals (IONS)
- TipRanks. All rights reserved.Mon, 18 Jul 2022 03:16 GMT Illumina (ILMN) Gets a Hold Rating from SVB Securities
- TipRanks. All rights reserved.Fri, 20 May 2022 01:10 GMT Illumina (ILMN) Receives a Hold from Credit Suisse
- TipRanks. All rights reserved.Tue, 10 May 2022 12:05 GMT Analysts Offer Insights on Healthcare Companies: Heska (HSKA), Illumina (ILMN) and Owens & Minor (OMI)
- TipRanks. All rights reserved.Sat, 07 May 2022 03:37 GMT Illumina (ILMN) Gets a Hold Rating from Robert W. Baird
- TipRanks. All rights reserved.Wed, 30 Mar 2022 09:07 GMT OTR Global Upgrades Illumina (ILMN) to Buy
- TipRanks. All rights reserved.Thu, 03 Mar 2022 01:10 GMT Illumina (ILMN) was Upgraded to a Hold Rating at Credit Suisse
- TipRanks. All rights reserved.Thu, 06 Jan 2022 14:05 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: BioMarin Pharmaceutical (BMRN), Illumina (ILMN) and Catalent (CTLT)
- TipRanks. All rights reserved.Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.